Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GBA1 | P04062 | 2/20 | 0.53 |
| ▸ | MC4R | P32245 | 1/20 | 0.41 |
| ▸ | SLC18A3 | Q16572 | 1/20 | 0.41 |
| ▸ | TACR3 | P29371 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | CCR3 | P51677 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14256284 | 1.00 | GBA1 (0.53) | GBA1MC4RSLC18A3TACR3MEN1 | |
| SCHEMBL19190084 | 1.00 | GBA1 (0.53) | GBA1MC4RSLC18A3TACR3MEN1 | |
| SCHEMBL14256047 | 0.88 | GBA1 (0.59) | GBA1MC4RCCR3 | |
| SCHEMBL19189701 | 0.84 | TRPA1 (0.39) | GBA1 | |
| SCHEMBL18663528 | 0.84 | TRPA1 (0.39) | GBA1 | |
| SCHEMBL19189525 | 0.84 | GBA1 (0.38) | GBA1 | |
| SCHEMBL18663776 | 0.84 | GBA1 (0.38) | GBA1 | |
| SCHEMBL1742163 | 0.84 | GBA1 (0.63) | GBA1MC4RCCR3 | |
| Hydrochloric Acid SCHEMBL21523631 | 0.82 | GBA1 (0.61) | GBA1CCR3 | |
| SCHEMBL22030379 | 0.80 | GBA1 (0.50) | GBA1MC4RCCR3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3143875-B1 | NOVEL COMPOSITIONS FOR PREVENTING AND/OR TREATING DEGENERATIVE DISORDERS OF THE CENTRAL NERVOUS SYSTEM | AMICUS THERAPEUTICS INC (US) | 2020-05-27 | — | — | EP | disclosed |
| EP-3143875-A1 | NOVEL COMPOSITIONS FOR PREVENTING AND/OR TREATING DEGENERATIVE DISORDERS OF THE CENTRAL NERVOUS SYSTEM | Amicus Therapeutics, Inc. (US) | 2017-03-22 | — | — | EP | disclosed |
| WO-2008131859-A2 | USE OF CYCLICALLY SUBSTITUTED FUROPYRIMIDINE DERIVATIVES FOR TREATING PULMONARY ARTERIAL HYPERTONIA | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2008-11-06 | — | — | WO | disclosed |